Discontinued — last reported Q4 '17
Non-Current Assets
Intangibles (Net)
Bristol-Myers Squibb Intangibles (Net) decreased by 4.3% to $20.47B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 24.1%, from $26.96B to $20.47B. Over 4 years (FY 2020 to FY 2024), Intangibles (Net) shows a downward trend with a -18.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryMarket Position
SignalContext dependent
VolatilityModerate
First reportedQ3 2015
Last reportedQ4 2017
How to read this metric
High levels reflect significant investment in growth through acquisitions; changes indicate the impact of amortization or impairment charges.
Detailed definition
This includes the value of acquired intellectual property, such as patents, trademarks, and drug licenses, net of accumu...
Peer comparison
Very high in the pharmaceutical industry due to the reliance on patent-protected drug portfolios.
Metric ID:
intangible_assets_netHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $48.07B | $44.93B | $42.53B | $40.10B | $37.69B | $38.18B | $35.86B | $33.57B | $31.30B | $28.95B | $27.07B | $32.76B | $29.43B | $26.96B | $23.31B | $22.49B | $21.38B | $20.47B |
| QoQ Change | — | -6.5% | -5.3% | -5.7% | -6.0% | +1.3% | -6.1% | -6.4% | -6.8% | -7.5% | -6.5% | +21.0% | -10.2% | -8.4% | -13.6% | -3.5% | -4.9% | -4.3% |
| YoY Change | — | — | — | — | -21.6% | -15.0% | -15.7% | -16.3% | -16.9% | -24.2% | -24.5% | -2.4% | -6.0% | -6.9% | -13.9% | -31.4% | -27.4% | -24.1% |
Range$20.47B – $48.07B
CAGR-18.2%
Avg YoY Growth-17.6%
Median YoY Growth-16.6%
Current Streak6 quarters decline
Intangibles (Net) at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's intangibles (net)?
- Bristol-Myers Squibb (BMY) reported intangibles (net) of $20.47B in Q3 2025.
- How has Bristol-Myers Squibb's intangibles (net) changed year-over-year?
- Bristol-Myers Squibb's intangibles (net) decreased by 24.1% year-over-year, from $26.96B to $20.47B.
- What is the long-term trend for Bristol-Myers Squibb's intangibles (net)?
- Over 4 years (2020 to 2024), Bristol-Myers Squibb's intangibles (net) has grown at a -18.7% compound annual growth rate (CAGR), from $53.24B to $23.31B.
- What does intangibles (net) mean?
- The value of non-physical assets like patents and brand names, minus their amortized cost.